The treatment of neuropathic pain involves the use of drugs from several drug classes, including antidepressants, antiepileptic drugs, local anesthetics, dual-acting opioid analgesics, and opioid analgesics. Despite the increasing availability of generic analgesics from these drug classes, as well as the continued entrenchment of select therapies as key treatment options for neuropathic pain, unmet need for new analgesics—particularly those with novel mechanisms of action—remains, driven by the growing prevalence of the neuropathic pain patient population and the sizable percentage of patients refractory to current treatment.

Questions Answered:

  • What is the current state of treatment for neuropathic pain? What are interviewed experts’ opinions of current treatment options?
  • What are interviewed experts’ views on late-phase emerging therapies such as Pfizer / Eli Lilly’s tanezumab, Regeneron / Teva / Mitsubishi Tanabe Pharma’s fasinumab, Grünenthal’s cebranopadol, and Daiichi Sankyo’s mirogabalin as potential treatments for neuropathic pain?
  • What is the commercial potential of late-phase analgesic products in the neuropathic pain market should they launch?
  • How will the neuropathic pain therapy market evolve over the next decade in light of expanding generic competition and the entrance of new treatments through 2028?

Product Description:

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.

Primary research: Approximately 20 country-specific interviews with thought-leading neuropathic pain experts, pain specialists, and neurologists. Supported by survey data collected for other DRG research.

Epidemiology: Prevalence of neuropathic back pain, painful diabetic neuropathy, neuropathic cancer pain, and HIV/AIDS-related neuropathic pain by country; diagnosed prevalence of postherpetic neuralgia by country.

Forecast:Ten-year, top-down sales of key neuropathic pain therapies through 2028. Market segmentation of select neuropathic pain populations in the forecast base year (2018).

Emerging therapies: Phase III/PR: 5 drugs; Phase II: 15 drugs.

Table of contents

  • Disease Landscape & Forecast
    • Key Findings
      • Neuropathic Pain - Key Findings - June 2020
    • Key Updates
      • June 2020
      • December 2019
      • September 2019
      • June 2019
      • March 2019
    • Market Outlook
      • Key Findings
      • COVID-19: Areas of Potential Forecast Impact
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Neuropathic Pain?
        • What Factors Are Constraining the Market for Neuropathic Pain?
      • Drug-Class-Specific Trends
        • Antiepileptic Drugs
        • Antidepressants
        • Local Anesthetics
        • Subtype-Selective Sodium-Channel Antagonists
        • Anti-NGF Therapies
        • Dual-Acting Opioid Analgesics
        • Opioid Analgesics
        • TRPV1 Receptor Agonists
        • NSAIDs and COX-2-Selective NSAIDs
        • Market Outlook for Emerging Therapies for Neuropathic Pain
    • Forecast
    • Etiology and Pathophysiology
      • Disease Overview
      • Etiology of Select Neuropathic Pain Disorders
        • Diabetic Neuropathy
        • Postherpetic Neuralgia
        • HIV / AIDS-Related Neuropathic Pain
        • Neuropathic Cancer Pain
        • Neuropathic Back Pain
        • Complex Regional Pain Syndrome
        • Central Neuropathic Pain
      • Pathophysiology of Neuropathic Pain
        • Overview
        • Peripheral Sensitization
        • Central Sensitization
        • Immune and Glial Cell Activation
        • Genetic Factors
      • Clinical Presentation of Neuropathic Pain
      • Key Pathways and Drug Targets
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • HIV / AIDS-Related Neuropathic Pain
        • Neuropathic Back Pain
        • Neuropathic Cancer Pain
        • Painful Diabetic Neuropathy
        • Postherpetic Neuralgia
        • Other Neuropathic Pain
        • Diagnosed and Drug-Treated Populations
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • Antiepileptic Drugs
        • Antidepressants
        • Local Anesthetics
        • TRPV1 Receptor Agonists
        • Dual-Acting Opioid Analgesics
        • Opioid Analgesics
        • Nonpharmacological Treatment
      • Medical Practice
        • Overview
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Neuropathic Pain
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • Subtype-Selective Sodium-Channel Antagonists
        • NMDA Receptor Modulators
        • Anti-NGF Therapies
        • Opioid Analgesics
        • HGF Gene Therapy
        • Bisphosphonates
      • Early-Phase Pipeline Analysis
      • Key Discontinuations and Failures in Neuropathic Pain
    • Access & Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • Looking for More?
    • Methodology
      • Methodology
        • General Sources of Data
        • Agents Included in Our Market Analysis
        • Assumptions Related to Market Segmentation by Indication
        • Assumptions Related to Physicians' Coding of Prescription Drugs for Pain
        • Out-Year Forecasting
        • Primary Market Research
    • Appendix
      • Neuropathic Pain Bibliography

Author(s): Bethany A. Kiernan, PhD; Angela Sparrow, PhD; Andrea Witt, PhD; Sunali D. Goonesekera, SM; Natalie Taylor, PhD; Audreza Das, P.G. Dip; Niyati Khetarpal, Ph.D; Shefali Gulati, MBA Pharm

Bethany A. Kiernan, is a senior director in the central nervous system/ophthalmology disorders unit of Decision Resources Group. While at Decision Resources Group, Dr. Kiernan has covered the market dynamics of numerous indications, including schizophrenia, depression, migraine, multiple sclerosis, epilepsy, and other disorders. Dr. Kiernan’s previous experience includes eight years of scientific research conducted at Tufts University School of Medicine, Case Western Reserve University, and the College of the Holy Cross. Dr. Kiernan earned her degree from Case Western Reserve University.

Angela Sparrow provides expert insight and authors primary market research and forecasting content as a member of the Central Nervous System and Ophthalmology Team. During her time with the company, Angela has extensively covered migraine, contributing to numerous reports while staying up-to-date on the latest trends and news. Additionally, she provides detailed responses to client inquiries and has authored content focused on psychiatric indications, including opioid addiction and depression, as well as neuropathic pain. Dr. Sparrow holds a in behavioral neuroscience from the University of North Carolina at Chapel Hill and a Bachelor’s degree from Northeastern University. Before joining DRG, she was a postdoctoral fellow at McLean Hospital, Harvard Medical School, studying the role of kappa opioid receptors in addiction and withdrawal-induced depression.

Andrea S. Witt, is Therapy Leader of the Central Nervous System and Ophthalmology Disorders Portfolio at Decision Resources Group where she oversees a team of 14 Business Insights Analysts and Senior Directors responsible for market research encompassing Neurology, Psychiatry, Pain, and Ophthalmology.  Dr. Witt has been with Decision Resources Group for over 12 years, following CNS markets and trends. Her interests beyond specific CNS indications included the market potential for neuroprotectants and the impact of biomarkers on CNS markets. Dr. Witt’s research, analysis, and commentaries have appeared in Barron’s, Pharmaceutical Executive, PharmaVoice, Nature Medicine, and CNBC. Dr. Witt’s previous experience includes 10 years of scientific research conducted on neurodegenerative disorders at Harvard Medical School/Brigham and Women’s Hospital, Duke University, and the University of Texas-Southwestern Medical Center, where she earned her degree.

Sunali Goonesekera is an Associate Epidemiologist at Decision Resources Group. Sunali holds a Master’s degree in Epidemiology from the Harvard School of Public Health and a in Biology (Honors) from Dartmouth College. Prior to joining Decision Resources Group, Sunali conducted epidemiological research and lead authored two manuscripts on racial/ethnic disparities in metabolic diseases at the New England Research Institutes. She has contributed to multiple publications in peer-reviewed journals in epidemiology and in the biological sciences.

Natalie Taylor, is a Principal Business Insights Analyst with the central nervous system/ophthalmology disorders team at Decision Resources Group. She has over ten years of experience authoring primary and market research reports for pharmaceutical industry clients across multiple psychiatry, pain, neurology, and ophthalmology therapy areas. Prior to joining DRG, Dr. Taylor worked at QuintilesIMS as manager of the central nervous system portfolio of Disease Insights market forecasting offerings. She completed her in Physiology at Dartmouth College in Hanover, New Hampshire, where she studied the role of serotonergic neurons in the medullary raphe on modulating respiratory responses in mammals. She holds a in Biology from Dickinson College in Carlisle, Pennsylvania.

Audreza Das is a Senior Analyst in the CNS/Ophthalmology team at Decision Resources Group She has authored content across indications, including neuropathic pain, age-related macular degeneration, treatment-related depression, painful diabetic neuropathy, and migraine. Ms. Das has previously worked at Novo Nordisk, as a Market Analyst for European markets. Previous experience at a SME, included developing disease competitive landscapes, covering global conferences etc. Ms. Das received her degree in Biotechnology from Birla Institute of Technology, a deemed university and her Diploma in Cancer Immunology & Biotechnology from University of Nottingham.

"Niyati Khetarpal  is an analyst on the Central Nervous System, Pain, and Ophthalmology team at ;In this role, she conducts extensive secondary research to analyze and forecast pharmaceutical markets, with specific expertise in patent research. Prior to joining the company, Niyati obtained her doctorate from the International Centre for Genetic Engineering and Biotechnology for her research on Dengue virus vaccines. She received the Fulbright-Nehru doctoral scholarship in 2014 for her research on Dengue and West Nile virus envelope ;

Shefali Gulati, Associate analyst, is part of the Central Nervous System, Pain, and Ophthalmology team at Decision Resources Group. She is responsible for performing extensive secondary market research and analysis for major pharmaceutical markets. She comes with one year of experience working on multiple client projects revolving around opportunity assessment, competitive landscape, pipeline analysis, and key product profiling. She holds a MBA degree in Pharmaceutical Management from the National Institute of Pharmaceutical Education and Research (NIPER) in India and Bachelor’s in Pharmacy from DIPSAR.

Related Reports

Neuropathic Back Pain | Epidemiology | Extrapolated Worldwide Coverage

DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key neuropathic back...

View Details

Neuropathic Pain | Current Treatment | Detailed, Expanded Analysis (US)

Neuropathic pain (NP) is a heterogeneous disorder arising from a wide variety of diseases and conditions, and as a result, patient response to drug therapy i...

View Details